Srpx2 Antibody

What is SRPX2 and why is it important in research?

SRPX2 (sushi repeat containing protein X-linked 2) is a secreted protein of approximately 53 kDa that functions as a ligand for the urokinase plasminogen activator surface receptor . It is primarily expressed in neurons of the rolandic area of the brain and has been implicated in several critical biological processes . SRPX2 plays significant roles in:

• Synapse formation and protection against complement-mediated elimination in both thalamus and cortex

• Angiogenesis through promotion of endothelial cell migration and vascular network formation

• Cellular migration and adhesion processes

• Neurodevelopment, particularly in the perisylvian region critical for language and cognitive development

The gene has been associated with Rolandic epilepsy, impaired intellectual development, and speech dyspraxia, making SRPX2 antibodies essential tools for investigating the molecular mechanisms of these conditions .

What applications are SRPX2 antibodies suitable for?

SRPX2 antibodies have been validated for multiple experimental applications in neuroscience, developmental biology, and molecular pathology research :

• Western Blot (WB): Typically used at concentrations of 1-2 μg/mL to detect the 53 kDa SRPX2 protein in tissue lysates

• Immunohistochemistry (IHC-P): Effective at concentrations starting from 5 μg/mL for visualizing SRPX2 expression patterns in fixed tissue sections

• Immunofluorescence (IF): Generally used at starting concentrations of 20 μg/mL for cellular localization studies

• ELISA: For quantitative detection of SRPX2 in biological samples

• Immunoprecipitation (IP): For isolation of SRPX2 protein complexes, particularly when studying protein-protein interactions

When designing experiments, it's important to select antibodies that have been validated for your specific application and species of interest, as reactivity has been confirmed for human, mouse, and rat samples .

What subcellular localization pattern should I expect when using SRPX2 antibodies?

When performing immunocytochemistry or immunofluorescence with SRPX2 antibodies, you should expect a mixed subcellular localization pattern that reflects the protein's biology :

• Cytoplasmic staining: SRPX2 is present in the cytoplasm of expressing cells, particularly neurons

• Extracellular/secreted pattern: As SRPX2 is a secreted protein, staining may also be detected in the extracellular space

• Cell surface localization: Some SRPX2 can be detected at the cell surface, consistent with its role as a ligand for cell surface receptors

• Synaptic localization: SRPX2 is found at synapses, where it plays a role in synapse formation and protection

When analyzing immunofluorescence results, punctate staining that shows correlation with synaptic markers (like VGlut1/VGlut2) would be consistent with SRPX2's biological function . Additionally, SRPX2 puncta show high correlation with C1q puncta but minimal correlation with C3 puncta, reflecting its specific interaction with C1q in the complement pathway .

How can I optimize SRPX2 antibody-based co-immunoprecipitation to study protein-protein interactions?

For effective co-immunoprecipitation (co-IP) of SRPX2 and its binding partners:

• Consider using a tagged SRPX2 approach: Native anti-SRPX2 antibodies may not be optimal for IP. Research has shown success using SRPX2-FLAG constructs for reliable immunoprecipitation with anti-FLAG antibodies .

• Alternative strategy using CRISPR: Generate a FLAG-tagged knockin model at the endogenous SRPX2 locus to maintain physiological expression levels. This approach has been validated for studying SRPX2 interactions with complement components .

• Recommended buffer conditions:

  • Use mild lysis buffers containing 1% NP-40 or 0.5% Triton X-100

  • Include protease inhibitors to prevent degradation

  • For investigating complement interactions, consider calcium-containing buffers as C1q binding may be calcium-dependent

• Validation approaches:

  • Perform reciprocal IPs (pull down with anti-C1q and probe for SRPX2)

  • Include appropriate negative controls (IgG control, lysates from SRPX2-deficient cells)

  • Confirm specificity by showing absence of co-IP signal in samples lacking the epitope tag

This methodology has successfully demonstrated that SRPX2 binds to C1q but not C3, providing insight into how SRPX2 regulates the complement pathway at synapses .

What are the key considerations for using SRPX2 antibodies in neuronal synapse quantification studies?

When studying SRPX2's role in synapse formation and elimination using antibody-based approaches:

• Multi-label immunofluorescence strategy:

  • Co-stain with pre- and post-synaptic markers (VGlut1/2 and PSD95) to identify mature synapses

  • Include complement component markers (C1q, C3) to assess pathway activation

  • Incorporate microglial markers (Iba1, CD68) when investigating synapse elimination

• Quantitative analysis methods:

  • Use cross-correlation analysis to measure colocalization between SRPX2 and synaptic markers

  • Employ synaptosome preparations followed by Western blotting to biochemically assess SRPX2 enrichment at synapses

  • Consider super-resolution microscopy techniques for more precise localization

• Control experiments:

  • Include SRPX2 knockout/knockdown conditions to establish specificity

  • Use both cortical and thalamic tissue preparations, as SRPX2 effects differ between regions

  • Compare retinogeniculate and thalamocortical synapses, which show differential sensitivity to SRPX2 modulation

• Critical considerations:

  • Different synapse types (excitatory vs. inhibitory, thalamocortical vs. corticocortical) show differential dependency on SRPX2

  • Developmental timing is crucial, as SRPX2's effects on synapse elimination are often transient and age-dependent

  • When quantifying microglial engulfment of synapses, normalize to microglial volume to account for potential differences in microglial morphology

How does SRPX2 function relate to complement pathway regulation, and how can this be studied?

SRPX2 has been identified as a neuronal complement inhibitor that regulates complement-dependent synapse elimination . To investigate this function:

• Mechanistic analysis approach:

  • Use in vitro complement activation assays (e.g., CH50 total hemolytic complement activity assay) to assess SRPX2's ability to inhibit complement pathway activation

  • Employ C2 cleavage assays to specifically study SRPX2's inhibition of C1 activity

  • Examine C3 deposition on synaptosomes in the presence/absence of SRPX2

• Genetic interaction studies:

  • Generate and analyze SRPX2 knockout models (SRPX2−/Y)

  • Compare with C3 knockout models (C3−/−)

  • Create double knockout models (C3−/−;SRPX2−/Y) to determine epistatic relationships

  • Assess phenotypes like synapse number, microglial engulfment, and axon segregation

• Quantitative parameters to measure:

  • C3 deposition levels on synapses

  • Microglial engulfment of synaptic material

  • Synapse density in relevant brain regions

  • Axon segregation in the lateral geniculate nucleus

  • Spine pruning in the somatosensory cortex

What are common issues with SRPX2 antibody specificity and how can they be addressed?

When working with SRPX2 antibodies, researchers may encounter specificity issues that can be addressed through several validation approaches:

• Common specificity concerns:

  • Cross-reactivity with other sushi domain-containing proteins

  • Background signal in secretory compartments

  • Variable detection based on glycosylation state of SRPX2

• Validation strategies:

  • Use SRPX2 knockout/knockdown samples as negative controls

  • Perform peptide competition assays to verify epitope specificity

  • Test multiple antibodies targeting different epitopes

  • Compare reactivity across multiple species if conducting comparative studies

• Application-specific optimizations:

  • For Western blot: Use reducing conditions and optimize transfer time for this 53 kDa protein

  • For IHC/IF: Test multiple antigen retrieval methods, as epitope accessibility can be affected by fixation

  • For secreted SRPX2 detection: Consider concentrating culture media or using heparin-based pull-down to enrich for secreted proteins

• Antibody selection criteria:

  • Choose antibodies validated specifically for your application (WB, IHC, IF)

  • Review published literature citing specific antibody catalog numbers

  • Consider monoclonal antibodies for higher specificity in certain applications

How should experimental design be adapted when studying SRPX2 in different neurological disease models?

SRPX2 has been implicated in various neurological conditions, requiring tailored experimental approaches:

• Epilepsy models:

  • Focus on rolandic brain regions implicated in SRPX2-associated epilepsy

  • Monitor both SRPX2 expression and complement activation markers

  • Assess both neuronal and microglial populations

  • Consider electrophysiological recordings to correlate SRPX2 levels with seizure activity

• Neurodevelopmental disorder models:

  • Employ developmental time-course analyses as SRPX2 effects are often age-dependent

  • Examine synapse morphology and density alongside synaptic function

  • Focus on language-relevant circuits when studying speech dyspraxia models

  • Include behavioral assessments to correlate molecular findings with cognitive outcomes

• Vascular and angiogenesis studies:

  • Combine SRPX2 antibodies with endothelial markers

  • Assess SRPX2's interaction with the urokinase plasminogen activator surface receptor

  • Monitor FAK phosphorylation as a downstream readout of SRPX2 signaling

  • Consider dual neurovascular assessment approaches as SRPX2 affects both systems

• Experimental controls and benchmarks:

  • Include positive controls for complement activation

  • Use region-specific analyses as SRPX2 effects differ between brain areas

  • Consider sex-specific analyses for this X-linked gene

  • When possible, correlate animal model findings with human patient samples

What quantitative approaches can accurately measure SRPX2-mediated effects on synaptic density and complement regulation?

To rigorously quantify SRPX2's functional effects:

• Synapse quantification methods:

  • Automated puncta analysis for co-localization of pre- and post-synaptic markers

  • Electron microscopy for ultrastructural analysis of synapse morphology

  • Array tomography for high-resolution multi-protein visualization

  • Electrophysiological recordings to correlate structural changes with functional outcomes

• Complement activation metrics:

  • Quantitative immunofluorescence for C1q and C3 deposition

  • Proximity ligation assays to detect SRPX2-C1q interaction in situ

  • Flow cytometry of synaptosomes to measure complement component binding

  • In vitro complement activity assays using purified components

• Microglial engulfment analysis:

  • 3D reconstruction of microglia-synapse interactions

  • Quantification of internalized synaptic proteins within microglial lysosomes

  • Live imaging of phagocytic events in slice cultures

  • Consider CD68/synaptic marker co-localization as a proxy for engulfment

• Statistical and normalization considerations:

  • Use appropriate statistical tests for non-normally distributed synapse data

  • Control for developmental stage when comparing across conditions

  • Account for regional variations in synapse density

  • Consider blinded analysis to prevent observer bias

These methodologies have been successfully employed to demonstrate that SRPX2 deficiency leads to increased complement deposition, enhanced microglial synapse engulfment, and altered synapse numbers in multiple brain regions .

How is SRPX2 research connecting with emerging therapeutics targeting the complement pathway?

Recent research on SRPX2's role as a complement inhibitor is opening new therapeutic avenues:

• Therapeutic relevance of SRPX2-complement interaction:

  • As SRPX2 inhibits the classical complement pathway by binding C1q, it represents a potential endogenous template for developing complement-targeting therapeutics

  • Understanding SRPX2's protective role at synapses may inform strategies to prevent pathological synapse loss in neurodegenerative diseases

  • The specificity of SRPX2 for the classical complement pathway offers advantages over broad complement inhibitors

• Current research directions:

  • Development of peptide or small molecule mimetics of SRPX2's complement-inhibitory domains

  • Investigation of SRPX2-derived recombinant proteins as potential therapeutic agents

  • Studies exploring how SRPX2 expression might be upregulated as a neuroprotective strategy

• Intersecting pathways:

  • Recent work has identified connections between SRPX2 and the Tie2 signaling pathway, with the Tie2-agonistic antibody MT-100 regulating SRPX2 as part of its mechanism

  • This connection has implications for treating neurovascular conditions and demonstrates how SRPX2 research is linking previously separate biological pathways

• Experimental approaches to explore therapeutic potential:

  • Use of recombinant SRPX2 in complement-dependent disease models

  • Screening for small molecules that stabilize SRPX2-C1q interaction

  • Development of cell-specific SRPX2 delivery systems targeting neurons or endothelial cells

What specialized techniques are needed to study SRPX2's dual roles in neural and vascular systems?

SRPX2's involvement in both neural and vascular processes requires integrated experimental approaches:

• Neurovascular co-culture systems:

  • Establish neuron-endothelial cell co-cultures to study SRPX2's dual functionality

  • Monitor both synapse formation and angiogenic responses simultaneously

  • Assess secreted vs. cell-associated SRPX2 in these systems

  • Use conditioned media experiments to examine paracrine effects

• Advanced imaging approaches:

  • Employ intravital microscopy in transparent models (like zebrafish) to visualize SRPX2 dynamics in vivo

  • Use dual-reporter systems to track neuronal and vascular responses to SRPX2 manipulation

  • Apply tissue clearing methods combined with light-sheet microscopy for whole-tissue analysis

  • Consider correlation of SRPX2 expression with blood-brain barrier integrity markers

• Signaling pathway analysis:

  • Monitor FAK phosphorylation as a downstream effect of SRPX2 signaling

  • Assess PI3K/AKT/eNOS pathway activation, which has been linked to both vascular function and neuroprotection

  • Examine HGF signaling, as SRPX2 increases its mitogenic activity

  • Evaluate ROS production as a measure of cell stress response

• Disease model considerations:

  • Diabetes models provide opportunities to study SRPX2's neurovascular roles, as recently demonstrated with MT-100 studies

  • Stroke models can reveal SRPX2's potential in post-ischemic recovery through both neural and vascular mechanisms

  • Neurodevelopmental models allow examination of SRPX2's role in concurrent neural circuit and vascular network formation

How can high-throughput approaches be applied to expand our understanding of SRPX2 function and regulation?

To accelerate SRPX2 research, several high-throughput strategies can be employed:

• Proteomic approaches:

  • Proximity labeling (BioID, APEX) to identify the full range of SRPX2 interacting proteins beyond known partners like C1q

  • Phosphoproteomics to map signaling cascades downstream of SRPX2 activation

  • Secretome analysis to understand how SRPX2 modifies the extracellular environment

  • Cross-linking mass spectrometry to characterize SRPX2's protein interaction surfaces

• Transcriptomic methods:

  • Single-cell RNA sequencing to identify cell types most responsive to SRPX2 manipulation

  • Spatial transcriptomics to map SRPX2 expression patterns and effects in tissue context

  • Compare transcriptional profiles of SRPX2-deficient vs. wildtype tissues across development

  • RNA-seq of sorted synaptosomes to understand SRPX2's impact on synaptic gene expression

• Functional genomics screens:

  • CRISPR screens to identify genes modifying SRPX2 function or regulating its expression

  • shRNA libraries targeting complement pathway components to delineate SRPX2's specific interaction points

  • Reporter-based screens to identify compounds that modulate SRPX2 expression or function

  • Synthetic lethal screens in SRPX2-deficient backgrounds to uncover genetic dependencies

• Advanced imaging platforms:

  • High-content screening of SRPX2 effects on synapse formation and elimination

  • Automated analysis of neuronal morphology and vascular network formation

  • Multiplexed antibody-based imaging to simultaneously track multiple components of the SRPX2-complement-synapse axis

  • Longitudinal live-cell imaging to capture dynamic aspects of SRPX2 function

These approaches promise to expand our understanding of SRPX2 biology beyond its currently established roles in complement regulation, synapse formation, and angiogenesis, potentially revealing new therapeutic opportunities.